NRx Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, NRx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $42. The average 1-year stock price forecast is 902.39% higher than the current stock price, while the lowest is $25 (+496.66%) and the highest is $49 (+1,069.45%).

Price Target: $42 (+902.39%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25	$42	$47	$49
Change	+496.66%	+902.39%	+1021.7%	+1069.5%

Analyst Ratings

The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	4	4	4	4	4
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $45	Buy	Reiterates	$45	+973.99%	Jun 25, 2026
Thomas Shrader BTIG	BTIG	Buy Maintains $25	Buy	Maintains	$25	+496.66%	Jun 23, 2026
Elemer Piros Lucid Capital	Lucid Capital	Buy Initiates $49	Buy	Initiates	$49	+1,069.45%	May 13, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Buy Maintains $34	Buy	Maintains	$34	+711.46%	Apr 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

10.19M

from 1.23M

731.97%

from 1.23M

Revenue Next Year

165.60M

from 10.19M

1,524.90%

from 10.19M

EPS This Year

-0.36

from -1.34

EPS Next Year

0.50

from -0.36

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	1.23M	10.19M
Revenue Growth	-	-	-	-	-	731.97%
Gross Profit	-	-	-	-	720.00K	6.57M
Gross Margin	-	-	-	-	58.78%	64.50%
Operating Income	-94.43M	-44.34M	-27.59M	-19.70M	-16.19M	-17.92M
Net Income	-93.06M	-39.75M	-30.15M	-25.13M	-28.62M	-14.73M
EPS	-	-	-	-	-1.34	-0.36
Free Cash Flow	-89.80M	-28.24M	-11.47M	126.25K	-805.88K	-13.20M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	21.7M
Avg	10.2M
Low	4.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	1,671.4%
Avg	732.0%
Low	248.7%

EPS Forecast

EPS	2026	2027	2028
High	-0.36
Avg	-0.36
Low	-0.36

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-